This is a working overview of LC-MS/MS, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2025-12-12. Anything still debated is marked as such rather than presented as settled.
Most published work on SR9009 consists of preclinical studies. It is widely sold as a research chemical, a category that does not imply safety, efficacy, or pharmaceutical-grade quality. Sports anti-doping organizations have listed SR9009 as a prohibited substance, and its presence in an athlete sample can lead to sanctions. Legal status differs by country; in several jurisdictions it is not approved for human consumption and may be treated as an unapproved new drug.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not a steroid, peptide, or natural hormone. In scientific literature, it appears under the code SR9009 and in non-scientific contexts as Stenabolic. The compound was identified through chemical screening efforts aimed at targeting circadian clock components. Its status remains investigational, and no regulatory agency has approved it as a human medicine.
REV-ERB proteins help regulate daily cycles in gene expression, including genes tied to lipid and glucose metabolism. SR9009 binds these receptors and alters their activity in cell and animal experiments. Consequences observed in rodents include changes in skeletal muscle oxidative capacity, blood lipid levels, and exercise performance. The precise chain from receptor occupancy to whole-body effects is still an active area of study. Human responses cannot be assumed from rodent data.
SR9009 stability depends on temperature, moisture, light, and solvent. Solid material is generally kept cool and dry, while solutions may require protection from repeated warming and cooling. Degradation can appear as color changes, precipitate, or new chromatographic peaks. Researchers should follow supplier instructions and their own stability data. Long-term storage conditions for human use have not been established because the compound lacks approved clinical formulation.
SR9009 is supplied as a solid research chemical, often in milligram quantities. Laboratories typically weigh it in a controlled environment because fine powders can disperse. Stock solutions are commonly prepared in dimethyl sulfoxide and stored in small aliquots to reduce freeze-thaw cycles. Personal protective equipment and chemical fume hoods are standard when handling unknown or potent compounds. These practices address laboratory safety rather than human use.
| Property | Value | Notes |
|---|---|---|
| Common name | SR9009 | Also referred to as Stenabolic in non-scientific contexts. |
| Chemical class | Synthetic small molecule | Not a steroid or peptide hormone. |
| Receptor target | REV-ERBα and REV-ERBβ | Nuclear receptor agonist in preclinical studies. |
| Development status | Investigational | No approved human therapeutic indication. |
| Regulatory attention | Prohibited in sport | Listed by anti-doping authorities. |
Storage conditions for research-grade SR9009 generally involve a freezer at approximately minus twenty degrees Celsius, sometimes lower for long-term preservation. Containers should remain tightly closed and protected from light. Desiccants may be used to limit moisture uptake. Solutions are often stored in aliquots to avoid repeated warming and cooling. Stability data for the compound under various conditions are limited, so laboratories typically follow supplier recommendations and verify performance through periodic analytical checks rather than assuming indefinite stability.
Identity and purity testing for SR9009 commonly uses liquid chromatography coupled with tandem mass spectrometry. This method separates the compound from matrix components and detects it by mass-to-charge transitions, providing sensitive and specific confirmation. Nuclear magnetic resonance spectroscopy can support structural identification, while high-performance liquid chromatography with ultraviolet detection may estimate purity. Because online products labeled as SR9009 may contain other substances or no active compound at all, independent verification is important in research settings. Certificates of analysis are useful but not a substitute for in-house testing.
Laboratory samples of SR9009 are typically supplied as a white to off-white powder. The compound dissolves readily in organic solvents such as dimethyl sulfoxide and ethanol, while its solubility in water is low. Because of this solubility profile, researchers often prepare concentrated stock solutions in an organic solvent before diluting them into aqueous assay buffers. Light exposure, moisture, and repeated freeze-thaw cycles can degrade many small molecules, so handling procedures usually aim to minimize these factors. Purity is commonly checked before use.
SR9009 is a synthetic small molecule developed as a REV-ERB agonist. It binds to REV-ERBα and REV-ERBβ, nuclear receptors that help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, the compound alters lipid and glucose handling and influences skeletal muscle oxidative capacity. Its exact effects in humans remain largely uncharacterized because controlled clinical trials have not been reported. The molecule is frequently described in preclinical literature as a metabolic modulator.
Research interest in SR9009 grew from studies showing improved running endurance in mice after short treatment periods. Those experiments linked the compound to increased mitochondrial content and fatty acid oxidation in muscle, but the findings come from animal models and specific dosing schedules. Independent replication has been limited, and the pathways connecting REV-ERB activation to exercise performance are still being mapped. Whether similar responses occur in humans is an open question.
=== Biosynthesis === The biosynthetic route of curcumin is uncertain. In 1973, Peter J. Roughley and Donald A. Whiting proposed two mechanisms for curcumin biosynthesis. The first mechanism involves a chain extension reaction by cinnamic acid and 5 malonyl-CoA molecules that eventually arylize into a curcuminoid. The second mechanism involves two cinnamate units coupled together by malonyl-CoA. Both use cinnamic acid as their starting point, which is derived from the amino acid phenylalanine. Plant biosynthesis starting with cinnamic acid is rare compared to the more common p-coumaric acid. Only a few identified compounds, such as anigorufone and pinosylvin, build from cinnamic acid.
== Hospital Facilities == .Theodor Bilharz research Institute Hospital is a tertiary hospital in Waraq El-Hadar, Giza, Egypt. · Six surgical theatres .Three ICU units ( 11 beds general medical ICU, 4 beds Surgical post-operative and 12 beds Hepatic ICU) .240 beds of Hepatology, Nephrology, General Medicine, Urosurgery, General Surgery, Intensive Care Unit. .Diagnostic Radiology department. . Interventional Radiology Unit. · Endoscopic facilities (gastroduodenoscopy, colonoscopy and ERCP) with ultrasonography and Doppler-electrocardiography. · Laparoscopic facilities for diagnostic and therapeutic purposes. · Minimal invasive urosurgery utilizing ureterorenoscopy; nephroscope and cystoscope, under fluoroscopic and endo-camera guidance. · Blood gas monitoring with estimation of serum electrolytes. · Fluoroscopy guided angio-table. · Twenty machines for haemodialysis. . Blood bank and various laboratories
1962 Pittsburgh Award 1963 Election to membership in the National Academy of Sciences 1963 Borden Medal 1963 Chancellors Medal, University of Pittsburgh 1972 Mellon Lecture, University of Pittsburgh 1976 Senior Scientist Award, Alexander Von Humboldt Foundation, Bonn, West Germany 1981 Third Alan E. Pierce Award by the American Peptide Chemists 1983 Japan Society for the Promotion of Sciences Fellowship Award 1987 First Huggins Memorial Award, University of Pittsburgh
Recently, the MMP3 gene was shown to be down-regulated in individuals with cleft lip and palate when compared to controls, reinforcing the nature of cleft lip/palate as a condition resulting from insufficient or defective embryonic tissue remodeling.
while fresh citrus (particularly lemons) cured scurvy, lime juice that had been exposed to light, air, and copper tubing did not – thus undermining the theory that citrus cured scurvy; fresh meat (especially organ meat and raw meat, consumed in arctic exploration) also cured scurvy, undermining the theory that fresh vegetable matter was essential to preventing and curing scurvy; increased marine speed via steam shipping, improved nutrition on land, reduced the incidence of scurvy – and thus the ineffectiveness of copper-piped lime juice compared to fresh lemons was not immediately revealed. In the resulting confusion, a new hypothesis was proposed, following the new germ theory of disease – that scurvy was caused by ptomaine, a waste product of bacteria, particularly in tainted tinned meat. Infantile scurvy emerged in the late 19th century because children were fed pasteurized cow's milk, particularly in the urban upper class. While pasteurization killed bacteria, it also destroyed vitamin C. This was eventually resolved by supplementing with onion juice or cooked potatoes. Native Americans helped save some newcomers from scurvy by directing them to eat wild onions.
Sources: en.wikipedia.org
== Bromine-77 == Bromine-77 is the most stable radioisotope of bromine, with a half-life of 57.04 hours. Although β+ decay is possible for this isotope, about 99.3% of decays are by electron capture. Despite its complex emission spectrum, featuring strong gamma-ray emissions at 239, 297, 521, and 579 keV, 77Br was used in SPECT imaging in the 1970s. However, except for longer-term tracing, this is no longer considered practical due to the difficult collimator requirements and the proximity of the 521 keV line to the 511 keV annihilation radiation related to the β+ decay. The Auger electrons emitted during decay are nevertheless well-suited for radiotherapy, and 77Br can possibly be paired with the imaging-suited 76Br (produced as an impurity in common synthesis routes) for this application.
A biopharmaceutical, also known as a biological medical product, or biologic, is any pharmaceutical drug product manufactured in, extracted from, or semisynthesized from biological sources. Different from totally synthesized pharmaceuticals, they include vaccines, whole blood, blood components, allergenics, somatic cells, gene therapies, tissues, recombinant therapeutic protein, monoclonal antibodies, and living medicines used in cell therapy. Biopharmaceuticals can be composed of sugars, proteins, nucleic acids, or complex combinations of these substances, or may be living cells or tissues. They (or their precursors or components) are isolated from living sources—human, animal, plant, fungal, or microbial. They can be used in both human and animal medicine. Terminology surrounding biopharmaceuticals varies between groups and entities, with different terms referring to different subsets of therapeutics within the general biopharmaceutical category. The term biologics is often used more restrictively to mean biopharmaceuticals that are produced using recombinant DNA technology. Some regulatory agencies use the terms biological medicinal products or therapeutic biological product to refer specifically to engineered macromolecular products like protein- and nucleic acid-based drugs, distinguishing them from products like blood, blood components, or vaccines, which are usually extracted directly from a biological source. Biopharmaceutics is pharmaceutics that works with biopharmaceuticals. Biopharmacology is the branch of pharmacology that studies biopharmaceuticals.
Operational aircraft of the force may be far less than official figures represent. According to a report in Le Figaro in April 2006, the Chadian Air Force consisted only of two Lockheed C-130 Hercules transports, one working Mil Mi-17 helicopter, and two non-working Mil Mi-24 helicopters. Later C-130 TT-PAF was lost in a landing accident at Abéché, on 11 June 2006.
== Etymology == The word poison was first recorded in English around the year 1200, meaning "a deadly potion or substance". It derives from the Old French poison or puison (12th century; Modern French: poison), originally meaning "a drink", particularly a medicinal one. By the 14th century, the term had come to signify "a (magic) potion" or "poisonous drink". These uses trace back to the Latin word potionem (nominative: potio), meaning "a drinking" or "a drink", and more specifically "a poisonous drink", as seen in the writings of Cicero. The Latin root comes from the verb potare, meaning "to drink". The use of poison as an adjective in the form poisonous dates back to the 1520s. The practice of using poison in combination with plant names began in the 18th century. For example, the term poison oak was first recorded in 1743, and poison ivy appeared in usage by 1784. The expression poison gas was first used during World War I in 1915.
Sources: en.wikipedia.org
CoA-glutathione + glutathione Thus, the two substrates of this enzyme are CoA and glutathione disulfide, whereas its two products are CoA-glutathione and glutathione. This enzyme belongs to the family of oxidoreductases, specifically those acting on a sulfur group of donors with a disulfide as acceptor. The systematic name of this enzyme class is CoA:glutathione-disulfide oxidoreductase. Other names in common use include glutathione-coenzyme A glutathione disulfide transhydrogenase, glutathione-coenzyme A glutathione disulfide transhydrogenase, glutathione coenzyme A-glutathione transhydrogenase, glutathione:coenzyme A-glutathione transhydrogenase, coenzyme A:oxidized-glutathione oxidoreductase, and coenzyme A:glutathione-disulfide oxidoreductase. This enzyme participates in cysteine metabolism and glutathione metabolism.
==== MeSH E05.478.567 – immunoassay ==== MeSH E05.478.567.320 – immunoblotting MeSH E05.478.567.320.200 – blotting, western MeSH E05.478.567.320.200.200 – blotting, far-western MeSH E05.478.567.350 – immunoenzyme techniques MeSH E05.478.567.350.170 – enzyme-linked immunosorbent assay MeSH E05.478.567.350.180 – enzyme multiplied immunoassay technique MeSH E05.478.567.380 – immunosorbent techniques MeSH E05.478.567.380.360 – enzyme-linked immunosorbent assay MeSH E05.478.567.380.810 – radioallergosorbent test MeSH E05.478.567.380.825 – radioimmunoprecipitation assay MeSH E05.478.567.380.830 – radioimmunosorbent test MeSH E05.478.567.639 – radioimmunoassay MeSH E05.478.567.639.405 – immunoradiometric assay MeSH E05.478.567.639.810 – radioallergosorbent test MeSH E05.478.567.639.825 – radioimmunoprecipitation assay MeSH E05.478.567.639.830 – radioimmunosorbent test
=== Therapeutics === Numerous natural and synthetic 2,5-DKPs are bioactive. These small, conformationally rigid, chiral templates have multiple H-bond acceptor and donor functionality and have multiple sites for structural elaboration of diverse functional groups with defined stereochemistry. These characteristics not only enable them to bind with high affinity to a large variety of receptors, showing a broad range of biological activities, but also allow the development of the drug-like physicochemical properties required for the multiobjective optimization process of transforming a lead to a drug product. The structure–activity relationship (SAR) has been explored for many of these 2,5-DKP templates, and several have been developed into clinical drugs. These include tadalafil (a PDE5 inhibitor for erectile dysfunction), retosiban (an oxytocin antagonist for preterm labor), aplaviroc (a CCR5 antagonists for HIV), epelsiban (an oxytocin antagonist for premature ejaculation) and the experimental cancer drug plinabulin (NPI-2358/KPU-2) that is active in multidrug-resistant (MDR) tumor cell lines.
Sources: en.wikipedia.org
It is a synthetic compound studied as an agonist of REV-ERB nuclear receptors. It is not an approved medicine and has mainly been examined in laboratory and animal research.
No. It is a small molecule that binds nuclear receptors involved in circadian regulation. Its classification differs from anabolic steroids or peptide hormones.
Published human clinical trial data are lacking. Most safety and activity information comes from preclinical models, so effects in people remain uncertain.
Laboratories commonly use liquid chromatography coupled with mass spectrometry to detect SR9009. The method can identify the compound and estimate concentration in a sample. Detection limits depend on the matrix and instrument.